Breaking News

Johnson & Johnson drafted by the Medicines Agency

The European Medicines Agency has announced that blood clots should be listed as a “very rare side effect” of the US vaccine. The distribution of Johnson & Johnson vials should therefore resume.

The European Medicines Agency has announced that blood clots should be listed as a “very rare side effect” of the US vaccine. The distribution of Johnson & Johnson vials should therefore resume.

(pj with AFP) – On the side of the European authorities in charge of vaccine orders for member states, some had to blow a big blow to the announcement of the European Medicines Agency (EMA) on Tuesday afternoon. Yes, the Johnson and Johnson vaccine has always the green light to be employed within the EU. Phew, Europe has ordered 200 million doses. And Luxembourg should receive 276,156 doses on this lot.

However, the EMA said it had established a “possible link” between the US laboratory’s vaccine and “very rare cases of unusual blood clots associated with low blood platelets”. Clots which, in the eyes of the European regulator, should “be listed as very rare side effects of the vaccine”. But the main message remains the confirmation that “the overall benefit-risk ratio remains positive” to vaccines which the United States had suspended use at the end of last week before the laboratory ceased distribution in Europe.

Johnson & Johnson’s chief financial officer said the lab remained “fully confident” about its vaccine against covid-19. A confidence that Luxembourg had continued to grant, even after Denmark in turn had decided to suspend vaccination with the serum developed in the United States. Nowadays, 165,515 anti-covid doses were injected in the Grand Duchy (all laboratories combined).


Tags

Related Articles

Back to top button
Close
Close